Press release
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC on "Global Pulmonary Arterial Hypertension Market- Forecast to 2027'' https://www.globalmarketestimates.com/market-report/pulmonary-arterial-hypertension-market-3787
By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE - 5 Inhibitors, Prostacyclin and Prostacyclin Analogs, and SGC Stimulators), By Type (Branded and Generics), By Route of Administration (Oral, Intravenous/ subcutaneous and Inhalational), By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East & Africa), End-User Landscape Analysis, Company Market Share Analysis, and Competitor Analysis
Key Market Insights
• As per the type outlook, the generics segment is expected to be the largest segment in the Pulmonary Arterial Hypertension market from 2022 to 2027
• The Asia Pacific region is analyzed to be the fastest-growing segment in the market
• As per the drug class outlook, the prostacyclin and prostacyclin analogs segment is expected to be the largest segment in the Pulmonary Arterial Hypertension market from 2022 to 2027
• North America (the United States, Canada, and Mexico) will have a dominant share in the global pulmonary arterial hypertension market from 2022 to 2027
• United Therapeutics Corporation, Bayer, Gilead Sciences, Inc., Johnson & Johnson, Viatris Inc., GlaxoSmithKline, Sandoz Inc. (Novartis), Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Teva Pharmaceutical Industries Ltd, among others, are the key players in the pulmonary arterial hypertension market.
Drug Class Outlook (Revenue, USD Billion, 2022-2027)
• Endothelin Receptor Antagonists (ERAs)
• PDE - 5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators
Type Outlook (Revenue, USD Billion, 2022-2027)
• Branded
• Generics
Route of Administration Outlook (Revenue, USD Billion, 2022-2027)
• Oral
• Intravenous/ subcutaneous
• Inhalational
Regional Outlook (Revenue, USD Billion, 2022-2027)
North America
• The U.S.
• Canada
• Mexico
Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC
Central & South America
• Brazil
• Argentina
• Rest of CSA
Middle East & Africa
• Saudi Arabia
• UAE
• Rest of MEA
Contact: Yash Jain
Email address: yash.jain@globalmarketestimates.com
Phone Number: +1 6026667238
B-502, Kemp Plaza, Mindspace, Malad West, Mumbai: 400 064, India
Global Market Estimates is an India based market research and consulting company. The company provides syndicated research reports, customised research reports and consulting services to their clients and helps them achieve their business goals on a commercial level. Global Market Estimates database is used by the world's well known and prolific academic institutions and Fortune 500 companies to understand the global and regional business environment to excel in their business goals.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Pulmonary Arterial Hypertension Market Size here
News-ID: 2619697 • Views: …
More Releases from Global Market Estimates Research & Consultants

Global Market Estimates Hosts Exclusive Webinar on Future Trends in Quick Commer …
Gain Strategic Insights and a Comprehensive Report on August 1st
Global Market Estimates (GME) is excited to announce an exclusive webinar, "Future Trends in the Global Quick Commerce Market: Forecasts to 2029," scheduled for August 1, 2024, at 11am EST. This insightful session will feature Mr. Yash Jain, Director - Global Accounts & Strategic Advisory.
For a registration fee of USD 499, attendees will receive a comprehensive report valued at USD 5,450,…

Global Flare Monitoring Market Size & Trends
According to a new market research report published by Global Market Estimates, the global flare monitoring market is expected to grow at a CAGR of 6.5% from 2024 to 2029.
Global flare monitoring market growth is driven by factors such as safety and risk management and growing emphasis on reduction of emissions.
Unlock the Executive Summary of the report at only USD 249. Book a call now: https://tidycal.com/yashsushiljain/unlock-strategic-insights-press-release
Key Market Insights
• As per…

Global Fiber Optic Component System Market Size & Trends
According to a new market research report published by Global Market Estimates, the global fiber optic component system market is expected to grow at a CAGR of 8.46 % from 2024 to 2029.
Global fiber optic component system market growth is driven by factors such as growing demand for safety regulations and technological developments.
Unlock the Executive Summary of the report at only USD 249. Book a call now: https://tidycal.com/yashsushiljain/unlock-strategic-insights-press-release
Key Market…

Global Rechargeable Battery Market Size & Trends
According to a new market research report published by Global Market Estimates, the global rechargeable battery market is expected to grow at a CAGR of 15.4% from 2024 to 2029.
Rechargeable batteries have been growing in popularity due to their inherent superiority over disposable batteries in environmental pollution. As rechargeable batteries can be recharged after every use, they cause much lower environmental degradation as compared to disposable batteries, which are discarded…
More Releases for Pulmonary
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Embolism - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Pulmonary Embolism - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2017, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood…
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot
The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
Europe Pulmonary Drugs Market grows with incredible awareness about the treatmen …
The intensity of competition in the global pulmonary drugs market is exceptionally high with the presence of few dominant players. However, Transparency Market Research observes that the leading players are expected to lose their share in the overall market as patents for several drugs are poised to expire in the coming years. The top five players in the market are GlaxoSmithKline Plc., Boehringer Ingelheim GmbH, Astra Zeneca, Teva Pharmaceutical Industries…